Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low-dose metronomic, multidrug therapy

Cancer

Volumn 112, Issue 10, 2008, Pages 2228-2232

  Coleman, Morton ^a,b   Martin, Peter ^a   Ruan, Jia ^a   Furman, Richard ^a   Niesvizky, Ruben ^a   Elstrom, Rebecca ^a   George, Patricia ^a   Kaufman, Thomas P ^a   Leonard, John P ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Low dose chemotherapy; Lymphoma; Metronomic therapy; Oral chemotherapy; Oral combinational chemotherapy

Indexed keywords

ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; ONDANSETRON; PREDNISONE; PROCARBAZINE;

ADULT; ANEMIA; ARTICLE; BEDTIME DOSAGE; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HERPES ZOSTER; HISTOLOGY; HUMAN; LEUKOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MORNING DOSAGE; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; HUMANS; LYMPHOMA; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; PROCARBAZINE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 43049122747     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23422     Document Type: Article

References (28)

1. Pasmantier MW, Coleman M, Silver RT. Chemotherapy of the non-Hodgkins lymphoma. Med Clin North Am. 1976;60:1043-1082.
2. Coleman M, Armitage JO, Gaynor M, et al. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Semin Hematol. 1988;25:2-10.
3. Yi PI, Coleman M, Saltz N, et al. Chemotherapy for large cell lymphoma: a status update. Semin Oncol. 1990;17:60-73.
4. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with 3 intensive chemotherapy regimens for advanced non-Hodgkins lymphoma. N Engl J Med. 1998;328:1002-1006.
5. Fisher RI. Overview of non-Hodgkins lymphoma and biology, staging, treatment. Semin Oncol. 2003;2(suppl 4):3-9.
6. Sehn LH, Donaldson J, Chanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033.
7. Turman S, Coleman M, Silver RT, Pasmantier M. High dose methotrexate with citrovoram factor in adult resistant lymphoma. Cancer. 1977;40:2823-2828.
8. Schuster MW. The refractory patient: new treatment options. Oncology. 2003;17:1333-1335.
9. O'Connor OA, Hamlin P. New drugs for the treatment of advanced-stage diffuse large cell lymphoma. Semin Hematol. 2006;43:251-256.
10. George P, Coleman M. The C3 regimen for resistant lymphoma: daily oral etoposide, chlorambucil, procarbazine, and prednisone [abstract]. Proc Am Soc Clin Oncol. 1993;12. Abstract 1292.
11. Coleman M, Leonard JP, Lee C, et al. The PEP-C (C3) oral combination chemotherapy regimen for refractory/ relapsed lymphoma: daily prednisone, etoposide, procarbazine, and cyclophosphamide. Blood. 1999;94. Abstract 410-1.
12. Coleman M, Siegel M, Schuster M, et al. Oral combination chemotherapy with PEP-C (C3) for mantle cell lymphoma (MCL): daily prednisone, etoposide, procarbazine and cyclophosphamide. Proc Am Soc Clin Oncol. 2003;22. Abstract 2396.
13. Coleman M, Leonard JP, Furman RR, et al. Combination chemotherapy for refractory/relapsed lymphoma with the PEP-C (C3) regimen (daily prednisone, etoposide, procarbazine, cyclophosphamide: low dose continuous metronomic multidrug. Proc Am Soc Clin Oncol. 2006;25. Abstract 8064.
14. Hainsworth JD. Chronic administration of etoposide in the treatment of non-Hodgkins lymphoma. Leuk Lymphoma. 1993;10(suppl):65-72.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Workshop Group. J Clin Oncol. 1999;17:1244.
16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/Forms/CTCAEv3.pdf Accessed June 23, 2007.
17. Coleman M, Martin P, Ruan J, et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk lymphoma. 2008;49:447-450.
18. Boyd DB, Coleman M, Papish SD, et al. COPBLAM III: infusional combination chemotherapy for diffuse large cell lymphoma. J Clin Oncol. 1988;6:425-433.
19. Hollister D, Silver RT, Gordon B, Coleman M. Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer. 1982;50:1690-1894.
20. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low dose anti-angiogenesis/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 2002;13:12-15.
21. Shaked Y, Emmenegger U, Francia G, et al. Low dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005;65:7045-7051.
22. Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimen. Cancer Res. 2004;64:3994-4000.
23. Man S, Bocce G, Francia G, et al. Antitumor effects in mice of low dose (metronomic) cyclophosphamide administered through the drinking water. Cancer Res. 2002;62:2731-2785.
24. Emmenger U, Morton GC, Francia G, et al. Low dose metronomic daily cyclophosphamide and weekly tirpazamine: a well tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res. 2006;66:1664-1674.
25. Shaked Y, Emmengger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimen is associated with maximum antiangiogenic activity. Blood. 2005;106:3058-3061.
26. Kaufman H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 2004;104:2269-2271.
27. Buchstein R, Kerbel RS, Shaked Y, et al. High dose celecoxib and metronomic "low dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12:5190-5198.
28. Shamash J, Walewski J, Apostolidis J, et al. Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. Ann Oncol. 2000;11:857-860.